Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Abir Boussetta

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
La Tunisie Medicale|March 15, 2026
Epileptic child in remission: Ceiling effect of valproic acidMariem Kammoun, Rim Charfi, Abir Boussetta, et al.
Frontiers in Immunology|September 2, 2025
High prevalence of the hotspot complement factor I p.Ile357Met pathogenic variant in Tunisian atypical hemolytic uremic syndrome patients: report of three new cases and review of the literatureAsma Tajouri, Imen Ayadi, Rimeh BenBrahim, et al.
Pediatric Nephrology (Berlin, Germany)|May 13, 2022
ePHex: a phase 3, double-blind, placebo-controlled, randomized study to evaluate long-term efficacy and safety of Oxalobacter formigenes in patients with primary hyperoxaluriaGema Ariceta, Laure Collard, Saoussen Abroug, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
La Tunisie Medicale|March 15, 2026
Epileptic child in remission: Ceiling effect of valproic acidMariem Kammoun, Rim Charfi, Abir Boussetta, et al.
Frontiers in Immunology|September 2, 2025
High prevalence of the hotspot complement factor I p.Ile357Met pathogenic variant in Tunisian atypical hemolytic uremic syndrome patients: report of three new cases and review of the literatureAsma Tajouri, Imen Ayadi, Rimeh BenBrahim, et al.
Pediatric Nephrology (Berlin, Germany)|May 13, 2022
ePHex: a phase 3, double-blind, placebo-controlled, randomized study to evaluate long-term efficacy and safety of Oxalobacter formigenes in patients with primary hyperoxaluriaGema Ariceta, Laure Collard, Saoussen Abroug, et al.
Pageof 3